Immune Cell Subset Profiles in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts) Desensitized with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody) Followed by Transplantation (Tx)

被引：0
|
作者：
Ge, S. [1 ]
Chu, M. [1 ]
Guzman, A. D. [1 ]
Ortiz, E. D. [1 ]
Vo, A. [2 ]
Ammerman, N. [2 ]
Jordan, S. C. [2 ]
Toyoda, M. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Transplant Immunol Lab, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2020年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
D-92
引用
收藏
页码：900 / 901
页数：2
相关论文
共 28 条
  • [1] Monitoring Inflammatory Cytokines in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts) Desensitized with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody) Followed by Transplantation (Tx)
    Ge, S.
    Petrosyan, A.
    Chu, M.
    Ammerman, N.
    Vo, A.
    Zhang, X.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 901 - 901
  • [2] Pre- And Post-Transplant (Tx) Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody) Treatment Increased Regulatory T Cell (Treg) Percentage in CD4+T Cells in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts)
    Ge, S.
    Chu, M.
    Ortiz, E. D.
    Guzman, A. D.
    Vo, A.
    Ammerman, N.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 902 - 903
  • [3] Monitoring Inflammatory Cytokine Levels in Kidney Transplant Patients (KTx Pts) with Chronic Antibody Mediated Rejection (cABMR) Treated with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody).
    Ge, S.
    Petrosyan, A.
    Chu, M.
    Ammerman, N.
    Vo, A.
    Jordan, S. C.
    Zhang, X.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 661 - 661
  • [4] Clazakizumab (clz, Anti-il-6 Antibody) Treatment Affects Il-6/il-6r Signaling by Increasing Soluble Gp130 (sgp130) in Hla-sensitized Kidney Transplant Patients (hs Ktx Pts) Treated for Chronic Antibody-mediated Rejection (cabmr)
    Shin, B.
    Ge, S.
    Jimenez, A.
    Ammerman, N.
    Vo, A.
    Zhang, R.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 737 - 738
  • [5] The Effect of Daratumumab (Dara, Humanized Anti-CD38 Monoclonal Antibody) on Immune Cells In Vitro and in a HLA-Sensitized Kidney Transplant Patient (HS KTx Pt) Desensitized (DES) with Dara
    Ge, S.
    Chu, M.
    De Guzman, A.
    Ortiz, E.
    Vo, A.
    Ammerman, N.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 372 - 372
  • [6] CLAZAKIZUMAB® (ANTI-IL-6) FOR DESENSITIZATION OF HIGHLY-HLA SENSITIZED PATIENTS AWAITING KIDNEY TRANSPLANT (NCT03380962)
    Vo, Ashley
    Ammerman, Noriko
    Huang, Edmund
    Toyoda, Mieko
    Ge, Shili
    Peng, Alice
    Najjar, Reiad
    Williamson, Summer
    Myers, Catherine
    Sethi, Supreet
    Lim, Kathlyn
    Choi, Jua
    Jordan, Stanley
    TRANSPLANTATION, 2020, 104 (09) : S104 - S105
  • [7] Clazakizumab (CLZ, Anti-IL-6 Monoclonal Antibody) Treatment of Patients (Pts) with Chronic Antibody-Mediated Rejection (cABMR) Reduces Total Immunoglobulin (Ig) and Anti-HLA IgG Antibody Levels.
    Shin, B.
    Ammerman, N. F.
    Vo, A. A.
    Zhang, X.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 667 - 667
  • [8] Clazakizumab (Anti-IL-6) Induces Foxp3+Tregs in Highly HLA Sensitized Patients Desensitized for HLAi Transplantation (NCT03380962)
    Jordan, S. C.
    Ge, S.
    Ammerman, N.
    Toyoda, M.
    Huang, E.
    Peng, A.
    Najjar, R.
    Sethi, S.
    Williamson, S.
    Myers, C.
    Lim, K.
    Choi, J.
    Vo, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 899 - 899
  • [9] Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
    Vo, A. A.
    Ammerman, N.
    Huang, E.
    Toyoda, M.
    Ge, S.
    Peng, A.
    Najjar, R.
    Sethi, S.
    Williamson, S.
    Myers, C.
    Lim, K.
    Gillespie, M.
    Jordan, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 372 - 372
  • [10] Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR).
    Shin, B.
    Ge, S.
    Petrosyan, A.
    Ammerman, N. F.
    Vo, A. A.
    Jordan, S. C.
    Toyoda, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 452 - 452
123